CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

The CureMatch Story

The CureMatch Story
Press

The Rancho Santa Fe News interviews CureMatch CEO Blaise Barrelet to discuss his personal battle with Leukemia and the motivation behind the founding of CureMatch.

Rancho Santa Fe Resident Launches Company to Provide Personalized Cancer Care

By: Karen Billing
Rancho Santa Fe resident Blaise Barrelet recently launched CureMatch, a new company he believes could be the future of cancer treatment.

CureMatch is a decision support platform designed to offer personalized medicine in cancer care. Operating on the belief that cancer is a personal disease that shouldn’t be treated with a one-size fits all treatments and procedures, the software technology enables matched combination therapies that are unique for individual patients based on the molecular profile of the patient’s tumor.

“Matched combination has been shown to have higher response and survival rates than traditional chemotherapy or targeted mono-therapies,” Barrelet said.

Barrelet, a native of France, has lived in Rancho Santa Fe for 18 years. A self-described “tech guy” and “serial entrepreneur,” he has started several successful businesses, including WebSide Story in 1996, one of the first internet businesses in San Diego. The company was also one of the first to provide web analytics for websites and he ended up selling it to Adobe Software in 2004 in a billion-dollar deal.

Barrelet then retired a “little bit” but didn’t really like being sidelined so decided to get back in the game helping other start-up businesses. He founded Analytics Ventures about five years ago, a venture-formation fund that works with scientists to create new data-enabled technology and software businesses.

Barrelet’s latest venture, driven by a desire to help cancer patients, was a result of his own experience. Four years ago, while his wife was pregnant with their fourth child, he received the shocking diagnosis of Chronic Lymphocytic Leukemia (CLL).

“The doctor told me ‘There’s good news and bad news. The good news is: it takes time to kill you. The bad news is: there is no cure,’” Barrelet said. “At first I felt really numb, I didn’t understand, I had it all, I had fun building companies and I had made lots of money. My next reaction to cancer was anger: ‘Why me?’ The third reaction was: ‘I’m going to beat this.’”

He was fortunate to be living in San Diego, where the top CLL specialists in the world work at UC San Diego Moores Cancer Center. Barrelet wasn’t sure that chemo was the best course of action for him so he started the process of learning all he could about targeted-therapy drugs, drug combination therapy and the use of DNA sequencing.

The more he learned about the “amazing” and “phenomenal” developments in the cancer treatment field, and the more his health benefited from the alternative to chemotherapy, the more he was determined to start a company that would help others.

CureMatch uses technology originally created and licensed by a multi-disciplinary team at Moores Cancer Center and the San Diego Supercomputer Center.

Using the latest molecular profiling tools, such as next-generation sequencing, CureMatch identifies the unique nature of the patients’ tumor and helps personalize the most advanced treatment options, including targeted therapy and immunotherapy.

With combination therapy, it’s possible to use combinations of drugs to target multiple cancer mutations at the same time.

Barrelet said CureMatch is the result of his two incredibly smart co-founders: Igor Tsigelny and Razelle Kurzrock. Tsigelny, a research professor at San Diego SuperComputer Center and Moores Cancer Center, is world-renowned expert in structural biology, molecular modeling, bioinformatics and structure-based drug design. Kurzrock is a pioneer in pathology and combination therapy who serves as the director of the Center for Personalized Cancer Therapy and Clinical Trials Office and is senior deputy director for clinical science at Moores Cancer Center.

The way a non-medical person like Barrelet likes to explain what they do is by using the analogy of boats floating on water — cancer is the water that comes and punches holes in the boat. Every hole is a genetic aberration.

Barrelet compares chemo to using a bucket to bail water out of the boat as it is sinking and mono-target therapy can plug the biggest hole in the boat but water can still find a way in. Cancer treatment has changed and there are now 300 FDA-approved cancer drugs designed to go after the variety of different holes in a boat.

“What we’re doing at CureMatch with matched combination therapy is quite complex —effectively plugging every hole in the boat. Of the 300 cancer drugs there are 4.5 million possibilities to combine drugs. It’s so complex because there’s so much data,” Barrelet said. “We take the data and make insight out of it and figure out the best drugs for each patient.”

CureMatch produces the top 3 to 4 combinations for each patient and scores them with a unique scoring system to rank treatment options to optimize patient care. The patient then goes to their oncologist with actionable knowledge — it is not a substitute for the physician’s decision, but provides the physician with a score for any options they have in mind and provides new combinations of drugs.

With cancer care, Barrelet said he hopes to see something similar to what happened with HIV, which is now primarily treated by combination therapy due to patient advocacy.

“Cancer patients are the best ambassadors. When you know you’re going to die, you’re willing to do anything. That’s the best way to change things,” Barrelet said. “To me, it’s so enjoyable to do something using my skills, net worth and knowledge that is about more than just making money. This is about saving other people, empowering patients and making a difference.”

 Rancho Santa Fe Review

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data